key: cord-0979309-df74i3hb authors: Wanjarkhedkar, Pankaj; Sarade, Girish; Purandare, Bharat; Kelkar, Dhananjay title: A prospective clinical study of an Ayurveda regimen in COVID 19 patients date: 2020-10-19 journal: J Ayurveda Integr Med DOI: 10.1016/j.jaim.2020.10.008 sha: f671f1c82abfc76b18a55f94bdbe7fa8ad048aa3 doc_id: 979309 cord_uid: df74i3hb Introduction The ancient Indian system of medicine, Ayurveda has a treatment for symptom complexes of a variety of disease. One such combination of Ayurvedic medications has potential for use in COVID 19 infection, hence a prospective study was conducted with this formulation as an add on, in COVID positive patients in a dedicated COVID Hospital. Objective To evaluate the additional benefit of an Ayurvedic regime in COVID +ve patients on the basis of rate of clinical improvement. Methodology The Ayurvedic formulation was administered as an add on to Standard of Care in patients with mild to moderate symptoms, in this prospective, open label, comparative study. Control group received Standard of Care only. Results Patients receiving Dasamoolkaduthrayam Kashaya & Guluchyadi Kwatham in tablet form in addition to the standard of care showed a faster recovery from dyspnoea with reduced ageusia. Patients on the treatment group could be discharged earlier than those from the control group. Conclusion Addition of Dasamoolkaduthrayam Kashaya & Guluchyadi Kwatham to Standard of Care appeared to accelerate recovery of patients hospitalized for COVID 19 infection, in terms of reduction of symptoms and duration of hospital stay. It has been 6 months since the novel Corona Virus Disease (COVID 19) was declared as the pandemic by WHO [1] . To contain the pandemic, many countries including India, underwent a series of lockdowns. The strategies recommended for containing the disease included sanitization measures, social distancing, regular use of mask, testing and quarantine for suspected carriers [2] . A variety of therapeutic measures also have been deployed to prevent and treat the infection, but formal trials of known Ayurvedic formulations have not been done. In fact, the Govt. of India has not included Ayurvedic formulations in their recommendations for clinical management of COVID 19 [3] . The Indian Council of Medical Research (ICMR) had identified key areas of research to generate critical intelligence for prevention & control efforts. [4] The Ministry of AYUSH (Ayurveda, Yoga, Unani, Siddha & Homeopathy) has come up with recommendations for the prevention, (through boosting immunity) and symptomatic treatment of the disease. [5] Epidemiological studies conducted by Ministry of Health & Family Welfare (MoHFW), Government of India (GoI) have produced results parallel to those obtained elsewhere. [6] The Centre for Disease Control (CDC) observed that among hospitalized COVID patients, 81% cases fell in moderately symptomatic category [7] . It had been demonstrated that upper and lower respiratory tracts were the major targets of the novel Corona Virus [8] . The Ayurvedic system of medicine, recommends a variety of herbal formulations for the treatment of diseases affecting the respiratory tract; it was therefore postulated that a regime containing Dasamoolkaduthrayam Kashaya & Guluchyadi Kwatham considered among the best for treatment of respiratory diseases could be useful for COVID 19 patients. The current study was conducted to test this hypothesis. To determine the efficacy of an Ayurveda regime containing Dasamoolkaduthrayam Kashaya & Guluchyadi Kwatham in patients of COVID 19 infections, with mild and moderate symptoms. To determine the rate of resolution of symptoms in patients with the Ayurvedic formulation as an add on to Standard of Care compared to Standard of Care alone. It has been 6 months since the novel Corona Virus Disease (COVID 19) was declared as the pandemic by WHO [1] . To contain the pandemic, many countries including India, underwent a series of lockdowns. The strategies recommended for containing the disease included sanitization measures, social distancing, regular use of mask, testing and quarantine for suspected carriers [2] . A variety of therapeutic measures also have been deployed to prevent and treat the infection, but formal trials of known Ayurvedic formulations have not been done. In fact, the Govt. of India has not included Ayurvedic formulations in their recommendations for clinical management of COVID 19 [3] . The Indian Council of Medical Research (ICMR) had identified key areas of research to generate critical intelligence for prevention & control efforts. [4] The Ministry of AYUSH (Ayurveda, Yoga, Unani, Siddha & Homeopathy) has come up with recommendations for the prevention, (through boosting immunity) and symptomatic treatment of the disease. [5] Epidemiological studies conducted by Ministry of Health & Family Welfare (MoHFW), Government of India (GoI) have produced results parallel to those obtained elsewhere. [6] The Centre for Disease Control (CDC) observed that among hospitalized COVID patients, 81% cases fell in moderately symptomatic category [7] . It had been demonstrated that upper and lower respiratory tracts were the major targets of the novel Corona Virus [8] . The Ayurvedic system of medicine, recommends a variety of herbal formulations for the treatment of diseases affecting the respiratory tract; it was therefore postulated that a regime containing Dasamoolkaduthrayam Kashaya & Guluchyadi Kwatham considered among the best for treatment of respiratory diseases could be useful for COVID 19 patients. The current study was conducted to test this hypothesis. To determine the efficacy of an Ayurveda regime containing Dasamoolkaduthrayam Kashaya & Guluchyadi Kwatham in patients of COVID 19 infections, with mild and moderate symptoms. To determine the rate of resolution of symptoms in patients with the Ayurvedic formulation as an add on to Standard of Care compared to Standard of Care alone. J o u r n a l P r e -p r o o f Page2 Patients tested as COVID 19 positive using RT-PCR and admitted in a tertiary care hospital were screened for this prospective, open label interventional clinical trial. Inclusion criteria for the study were: 1. Patients of either sex between 18 and 65 years of age. 2. Those suffering from mild to moderate symptoms included patients of either sex, suffering from mild to moderate symptoms as per MoHFW -GoI guidelines[6] Exclusion criteria were: 1. Pregnant / Lactating mothers 2. Patients with co-morbidities like Chronic Obstructive Pulmonary disease (COPD), Ischemic Heart disease (IHD), Chronic Kidney Disease (CKD), Coagulopathy and Cancer 3. Patients with significant morbidity after oral surgery & not able to swallow were excluded. 4. Patients who were on immuno-suppressant, oral steroids or chemotherapy 5. Patients k/c/o Diabetes Mellitus (DM) taking insulin 6. Patients with Sr. Creatinine > 1.6 mg/dl, Sr. Sodium < 128 mEq/L Hemoglobin (HB) < 7.0 gm% SPO2 < 90% The patients were randomly allotted from the daily admission list by physicians who were not part of this study into treatment and control groups. Patients of both the groups received the Standard of Care (SoC), as per the ICMR guidelines. The SoC and Oxygen supplementation was decided by the treating physicians. The treatment group received the on Ayurveda regime that was a combination of two tablets (Tab.) viz., Tab. Dasamoolkaduthrayadi Kashaya + Tab. Guluchyadi Kwatham. These tablets were manufactured by GMP certified units. These formulations are in the market for more than two decades. Detailed formulation of the Ayurvedic products is given in Table 2 . Two tablets of each were administered 12 hourly after meals. The duration of treatment as recommended by guidelines is 7 days [9] . Total 112 patients were screened as per inclusion criteria, 11 failed the screening, and 101 patients recruited in the trial. Two patients complained about difficulty in swallowing the tablets and were discontinued on Day 3. Finally, 99 patients completed the study were analyzed. Out of 99 patients, 60 patients received Ayurveda regime as an add on, while 39 patients received only SoC . The treatment and control groups had similar demographic distribution. The biochemical and hematological parameters at baseline are shown in Table 4 . The median day of admission from the onset of symptoms was 6 th (range 1 st to 12 th ) in treatment group; while it was 5 th day (range 1 st to 16 th ) in control group. Patients with co-morbidities like Diabetes & Hypertension were 90.04%. Asthma & Hypothyroidism were the observed as other comorbidities among the rest. Fever, breathlessness, cough, ageusia, headache were the symptoms that were observed throughout the study. Table 5 shows the number of patients suffering from each of these on day 1,3 and 7 of treatment. The most common symptom was fever, while headache was experienced by the least number of patients. The percentage of patients suffering from breathlessness fell from 53% to 16 % to 1.6% on day 1,3 and 7 in the treatment group while in the control group the percentage fell from 46% to 38% to 28% respectively. Ageusia is considered a significant symptom of COVID 19, the percentage of patients J o u r n a l P r e -p r o o f Page3 suffer from the same reduced from 75% to 25% to 3.3 % in the treatment group while in the control group it fell from 46% to 36 % to 26%. In both groups there was a similar fall in the percentage suffering from fever. Charts 1, 2 and 3 show the response of patients in the treatment and control groups with respect to Breathlessness, ageusia and fever. Reductions in breathlessness and ageusia were statistically significant (p<0.001 Chi squared) at day 3 and day 7, while reduction in fever was not. Fever, Oxygen requirement (p=0.2 Mann -Whitney test), body-ache & fatigue (p=0.5 Chi squared), had similar response rate in both the groups [ Table 5 ]. Hiccups were reported by 2 patients on day 4 & 5 of the treatment, which was self-limiting. Salty taste (Lavanasyata) and Polydipsia (Talushoosha) was reported on day 3 & day 5 respectively, by 2 different patients in study group. Chest digital roentgenograms (X Ray) were compared in few patients. The patchy opacities were reduced without anti-viral drugs in study group on follow up Chest X-ray by Day 4. The observed changes were clinically significant; though statistically not analysed [Picture 1 & 2]. Median Hospital stay for COVID Pharyngitis patients in the study group was 5 days as compared to 7 days in the control group. The patients with COVID Pneumonia had the median hospital stay of 7 days in study group as compared to 8 days in control group. One patient in study arm was asymptomatic from Day 3 to Day 7; but had symptoms on Day 7; further treated with the same add-on regime, till the patient turned asymptomatic on Day 15 th . The disease progression was observed in 1 patient in control group; who later required intensive care unit had prolonged stay of 23 days. The percentage of co-morbidities was more in study group; despite that 1 of 60 patients in the study group required Remdesivir while 2 of 36 patients required it in the control group. 1 of 60 patients in study group required Remdesivir as well as Tocilizumab during hospital stay while 2 of 36 patients required the same in control group. This study was conducted after 4 months of COVID 19 pandemic alert; no specific antiviral treatment / vaccine had been recommended or made available by then [10] . This study was intended to explore the potential from Ayurveda with evidence over just experience based. This study was initiated after extensive discussions among the physicians from the departments of infectious disease, intensive care and Ayurveda of this institute. COVID 19 patients were presented with low grade fever, dry cough, muscle pain, or malaise. In some patients sore throat & headache were observed. Cough and shortness of breath were present without signs of severe pneumonia at presentation. Ageusia was observed predominantly [11, 12] ; anosmia in few. An European study mentioned that in mild to moderate COVID 19 category 88% patient had the gustatory dysfunction [13] . Page4 It was observed that dry cough was often associated with difficulty in breathing. Chest X Ray showed bilateral multifocal alveolar opacities. The radiological improvement observed on 4 th & 5 th day. Majority patients had elevated levels of C-reactive protein; few had elevated levels of d -dimer [14] . Ayurveda medicines used were indicated in Ayurveda texts [16, 17] ; scientific publications suggested analgesic, anti-pyretic, anti-platelet aggregation, anti-viral activity for Dasamoolkadutraya [18, 19, 20] & Guluchyadi Kwatham [21, 22] . The significant recovery in breathlessness and ageusia in the add-on arm reduced hospital stay for the patients. The early discharge from hospital was important in view of scarcity of Oxygen equipped beds. In India, only 3.2 hospital beds were available per 10,000 population and in Maharashtra, this number was 2 per 10,000 population [23] . The majority number of beds were mainly concentrated in urban India, than rural [24] . The reduced hospital stay could be directly proportional to availability of hospital beds for accommodating more needy patients. All over the world COVID 19, has shown a variable natural course, though a lot of effort has gone into attempts to identifying factors associated with higher morbidity or mortality, consensus is still awaited. Given these uncertainties, obtaining statistical significance in a series as small as this is difficult. A systematically randomized large sample study would be better with tighter controls would be preferred. However, the public response to the pandemic makes it difficult to strictly adhere to trial protocols. There is also need to compare haematological & biochemical parameters, before and after treatment which was not done. A comparative radiology imaging is also recommended for future studies. The present add-on Ayurveda regimen was the low risk & highly cost effective as it reduced hospital stay. No adverse effects observed in study group. Early clinical improvement in breathlessness was observed with the present add-on Ayurveda regimen. Ageusia reduced early with add-on Ayurveda regimen. The median duration of hospital stay was reduced; this factor is of importance in view of shortage of hospital beds in India. The learning from this study is the potential of Ayurvedic therapy in treating COVID 19. Percentage of Patients Suffering from Fever Treatment Control Percentage of patients suffering from Breathlessness Treatment COVID 19 in India: Potential Impact of the Lockdown and Other Longer-Term Policies; Publication of The Centre for Disease Dynamics Public Health approach of Ayurveda & Yoga for COVID 19 prophylaxis Pranab Chatterjee et al; The 2019 novel corona virus disease (COVID 19) pandemic: a review & current evidence Ministry of AYUSH; Government of India; Guidelines for Ayurveda practitioners for COVID 19 Clinical management protocol: COVID19, Ministry of Health & Family Welfare, Director General Health Sciences, Govt of India Interim Clinical Guidance for management of patients with confirmed Coronavirus disease (COVID 19) Clinical Care Guidance Novel Coronavirus (COVID19) Outbreak: A Review of the Current Literature Features, Evaluation & treatment Corona Virus (COVID19); NCBI Bookshelf. Statpearls (internet), treasure island(FL) A systematic review Smell & taste dysfunction in patients with COVID 19 Possible mechanism & implications Carlos del Rio; Mild or Moderate COVID19, NEJM Clinical characteristics of Corona Virus Disease 2019 in China Vagbhat-virachita Ashtanghridayam -Sarvangsundar commentary; Choukhambha Surabharati Publication, Varanasi 17. Sahastrayog -Publication by CCRAS Experimental evaluation of analgesic, anti-inflammatory & anti platelet potential of Dasamoola; JAIM Anti-viral & anti-proliferative in vitro activities of piperamides from black pepper Fresh Ginger anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines Experimental evaluation of anti-pyretic and analgesic activities of Amalakyadi gana: an Ayurveda formulation Chemistry & medicinal properties of Tinopsora cordifolia (Guduchi) COVID 19: Challenges & its consequences for rural health care in India State wise estimates of current hospital beds, ICU beds & ventilators in India: Are we prepared for a surge in COVID 19 We sincerely acknowledge COVID 19 Team; chief coordinator of COVID task force Dr. Sameer Jog and Dr. Parikshit Prayag & Dr. Pethe . We are thankful to Dr. Sindhu Shiralkar of Vaidya L B Shiralkar trust for the positive encouragement.